A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on Cleveland Clinic research.
Study Links the Gut Microbiome and Aggressive Prostate Cancer
The investigators’ findings suggest dietary interventions may help reduce disease risk.
Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer
Findings from a new study show that pharmacologically inhibiting the H6PD protein can reverse drug resistance in human-derived preclinical models of enzalutamide-resistant prostate cancer.
Is There a Link Between Prostate Cancer and COVID-19?
An Italian-led study published earlier this year reported that androgen deprivation therapy may play a protective role against the risk of SARS-CoV-2 infection. Using an expansive enterprise-wide COVID-19 testing registry, Cleveland Clinic researchers set out to validate this report. Eric Klein, MD, discusses their findings.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
New Genetic Test May Mean Better Outcomes in Advanced Prostate Cancer
A new test developed at Cleveland Clinic interrogates the HSD3B1 gene to determine if a prostate cancer patient has inherited the adrenal-permissive (1245C) or adrenal-restrictive (1245A) allele. The development of the test is an outgrowth of more than seven years of research at Cleveland Clinic.
Researchers Validate Link Between Genetic Variant and Poor Outcomes in Advanced Prostate Cancer
Metastatic prostate cancer patients with an adrenal-permissive variant of the HSD3B1 gene are more likely to have aggressive, early castration-resistant disease and shorter survival, a Cleveland Clinic-led study has found. The finding could help physicians identify patients most likely to benefit from escalated treatment.
A New Paradigm for Advanced Prostate Cancer Clinical Trials
If therapies for advanced prostate cancer — particularly those with curative intent for oligometastatic disease — are to progress, clinical trials will need to take into account what’s driving tumor progression, what treatment will add benefit, and for which patients, contends eminent cancer researcher Nima Sharifi, MD.
Functional PET Imaging to Identify Prostate Cancer Treatment Resistance
New findings suggest a noninvasive method of monitoring the metabolic status of prostate tumors in real time and have clear implications for the future of prostate cancer imaging.
Early Investigator Research Awards Expand Prostate Cancer Fellows Research
Two postdoctoral fellows in the laboratory of Nima Sharifi, MD, have received prestigious Department of Defense Prostate Cancer Research Program Early Investigator Research Awards in support of innovative prostate cancer work.
New Research Links Gene Variant to Deadly Prostate Cancer
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.